Great Plains Chapter of the American College of Cardiology

Latest in Cardiology from ACC.org

• ADHERE-ASCVD Analysis: Digital Outreach Improves Statin Refills Across Age Groups
  Digital outreach through a variety of formats may improve short-term statin refill consistently across a broad age range, according to a prespecified analysis of the ADHERE-ASCVD trial presented at AHA 2026 and simultaneously published in JACC.
• Intensive BP Lowering, Yoga-Based Cardiac Rehab Highlighted Among Late-Breaking Science at AHA 2026
  Intensive blood-pressure (BP) lowering therapy in patients with type 2 diabetes and a yoga-based cardiac rehabilitation program for people with heart failure and reduced ejection fraction (HFrEF) were among the hot topics in cardiovascular prevention included in a late-breaking clinical science session at AHA 2026.
• STREAM, eZ-PAVE Add New Insights Into Statin Therapy Treatment
  Discontinuing statin therapy in older adults with at least two chronic conditions but no known cardiovascular disease was noninferior to continuation with respect to major cardiovascular events or death from any cause at two years, according to findings from the STREAM trial presented at AHA 2026 and simultaneously published in NEJM.
• AHA 2026 Trials Examine Strategies to Improve Patient Care Post-Stroke
  From tackling blood clots to managing blood pressure (BP), three separate trials presented at AHA 2026 – REDUCE, OCEANIC-STROKE and OPTIMAL-STROKE – offer new insights into improving outcomes after stroke.
• Lp(a) HORIZON: Pelacarsen vs. Placebo in Patients With High Lp(a)
  Pelacarsen did not result in a lower risk of major adverse cardiovascular events compared with placebo in patients with preexisting cardiovascular disease and high lipoprotein(a) (Lp(a)) over a median follow-up period of approximately five years, based on findings from the Lp(a) HORIZON trial presented at AHA 2026 and simultaneously published in NEJM.